Here, we present the largest cohort of patients to date with blood samples and CHD to investigate the potential use of circulating activin A, CTGF, and sST2 levels as biomarkers associated with the development or presence of CHD, which is confirmed by echocardiography. This evidence concerns the gene CCN2 and coronary artery disorder.